NASDAQ · AGRX
Healthcare · Drug Manufacturers - Specialty & Generic
$1.51
Up+$0.05 (+3.42%)
Updated Aug 13, 2026, 6:34 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
AGRX does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning AGRX.
AGRX research
Company profile and research snapshot.
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 18, 2024 | Maxim Group | Hold | — |
| Sep 22, 2023 | Maxim Group | Buy | — |
| Jun 26, 2023 | HC Wainwright & Co. | Buy | — |
| Jun 7, 2023 | HC Wainwright & Co. | Buy | — |
| Dec 30, 2022 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Aug 26, 2024
Agile Therapeutics, a women's healthcare company, has been acquired by Insud Pharma, a global pharmaceutical group based in Spain. The former Agile shareholders will receive $1.52 per share in cash, and Agile will no longer be listed on any public market.
GlobeNewswire Inc. · Aug 3, 2024
The global mother and child healthcare market is expected to grow from USD 723.67 billion in 2023 to USD 2106.78 billion by 2033, driven by factors such as increasing birth rates, growing awareness of maternal health, and advancements in healthcare products.
GlobeNewswire Inc. · Jun 26, 2024
Agile Therapeutics will combine with Insud Pharma’s US Subsidiary, Exeltis, expanding an already significant Women’s Health/contraceptive portfolio
GlobeNewswire Inc. · May 15, 2024
First Quarter Net Revenue Increased 58% and Factory Sales Increased 3% from Fourth Quarter 2023
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AGRX.
No results
No recent SID articles mention AGRX.
